得克萨斯大学MD 安德森癌症中心发现,免疫疗法定向疗法组合提高了ATC存活率。 University of Texas MD Anderson Cancer Center finds immunotherapy-targeted therapy combination boosts ATC survival rates.

得克萨斯大学MD Anderson癌症中心的研究人员发现,将免疫疗法与有针对性的治疗相结合,可大大提高有塑料性甲状腺癌的患者的存活率。 Researchers at the University of Texas MD Anderson Cancer Center found that combining immunotherapy with targeted therapy significantly boosts survival rates for patients with anaplastic thyroid carcinoma (ATC). 在第二阶段的一项研究中,BRAF变异患者的总存活率中位数为43.2个月,答复率为50%。 In a Phase II study, patients with BRAF mutations had a median overall survival of 43.2 months and a 50% response rate. 这种综合治疗现已成为MD Anderson的护理标准,为个人化癌症治疗提供了新的途径。 This combination treatment is now the standard of care at MD Anderson, suggesting new avenues for personalized cancer treatment.